Home > Rheumatology > Novel biomarkers enable personalised medicine in early RA

Novel biomarkers enable personalised medicine in early RA

Presented By
Dr Patrick Vandormael, Hasselt University, Belgium
Conference
BCR 2022
Trial
CareRA
Antibodies against 3 University Hasselt (UH)-rheumatoid arthritis (RA) antigens were predictive of failure to achieve clinical remission, sustained clinical remission, and sustained low-disease activity following first-line therapy with methotrexate and glucocorticoids in patients with RA. These results provide an opportunity for personalised medicine, according to the authors [1]. Methotrexate plus glucocorticoids are the first-line therapy for patients with RA. “However, whether this therapy leads to clinical response is determined by a wait-and-see approach,” said Dr Patrick Vandormael (Hasselt University, Belgium). “If we could predict the effectiveness of methotrexate plus glucocorticoids in individual patients, we may initiate other therapies in case it is unlikely that a particular patient will respond to the standard first-line therapy.” The general hypothesis of the presented study is that autoantibodies can predict a lack of treatment response to...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on